We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-2 of 2

U.S. Supreme Court rules that a drug’s adverse event reports may be material to investors even though not "statistically significant"

  • Jones Day
  • -
  • USA
  • -
  • March 28 2011

On March 22, 2011, the U.S. Supreme Court issued its long-awaited opinion in Matrixx Initiatives, Inc. v. Siracusano (No. 09-1156

SEC alleges securities fraud by biopharmaceutical company and executives

  • Jones Day
  • -
  • USA
  • -
  • September 6 2011

On August 1, 2011, the SEC brought suit against Immunosyn Corporation, Argyll Biotechnologies LLC, and four executives, alleging that they had committed securities fraud related to misleading statements regarding the status of regulatory approvals during 200610

Current Search

Suggested Facets

Author

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy